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1,5, Erandi Lira-Navarrete2,5,
Thomas A Gerken3 and Ramon Hurtado-Guerrero1,4
4 Mucin-type O-glycosylation is a post-translational modification
5 (PTM) that is predicQ2 ted to occur in more than the 80% of the
6 proteins that pass through the Golgi apparatus. This PTM is
7 initiated by a family of polypeptide GalNAc-transferases
8 (GalNAc-Ts) that modify Ser and Thr residues of proteins
9 through the addition of a GalNAc moiety. These enzymes are
10 type II membrane proteins that consist of a Golgi luminQ3 al
11 catalytic domain connected by a flexible linker to a ricin type
12 lectin domain. Together, both domains account for the different
13 glycosylation preferences observed among isoenzymes.
14 Although it is well accepted that most of the family members
15 share some degree of redundancy toward their protein and
16 glycoprotein substrates, it has been recently found that several
17 GalNAc-Ts also possess activity toward specific targets.
18 Despite the high similarity between isoenzymes, structural
19 differences have recently been reported that are key to
20 understanding the molecular basis of both their redundancy
21 and specificity. The present review focuses on the molecular
22 aspects of the protein substrate recognition and the different
23 glycosylation preferences of these enzymes, which in turn will
24 serve as a roadmap to the rational design of specific
25 modulators of mucin-type O-glycosylation.
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40Introduction
41Polypeptide GalNAc-transferases (GalNAc-Ts) are a fam-
42ily of Golgi resident enzymes (20 in humans) that transfer a
43GalNAc moiety from UDP-GalNAc onto Ser or Thr resi-
44dues of their protein substrates. This process results in the
45synthesis of the Tn antigen (GalNAca1-O-Ser/Thr), which
46can be further elongated by the action of subsequent
47glycosyltransferases (GTs) [1,2]. Historically, this modifi-
48cation is known as mucin-type O-glycosylation (henceforth
O-glycosylation) as these glycans are abundant (>50% by
49weight) in mucins. As the GalNAc-Ts initiate and thus
50define sites of O-glycosylation in densely O-glycosylated
51proteins such as mucins, these enzymes must possess a
52range of properties in order to properly glycosylate their
53targets [2,3]. It is now known that the GalNAc-T isoen-
54zymes have different glycosylation preferences that allow
55them to be classified as: a) glycopeptide/peptide-preferring
56isoforms (e.g. GalNAc-T1 and GalNAc-T2); b) (glyco)
57peptide-preferring isoenzymes (e.g. GalNAc-T4); and c)
58strict glycopeptide-preferring isoenzymes (e.g. GalNAc-
59T7 and GalNAc-T10) [4]. This distinction is based on
60their activity against substrates lacking or containing one or
61more prior GalNAc-O-Ser/Thr moieties which allows them
62to be classified into early, intermediate or late GTs, repre-
63sentinga range inactivities against naked peptides/proteins
64to already highly glycosylated peptides/proteins (e.g. Gal-
65NAc-T2, GalNAc-T4 and GalNAc-T10 are early, interme-
66diate and late GTs, respectively) [1,4,5] (See Figure 1).
67The glycopeptide activities of the GalNAc-Ts have been
68further classified into two classes, based on their short-
69range (or neighboring) and long-range (or remote) glyco-
70sylating capabilities. The short-range glycosylation pre-
71ferences account for the glycosylation of glycopeptide
72substrates where the sugar moiety is bound to the cata-
73lytic domain (thus glycosylating 1–3 residues from the
74sugar), while the long-range glycosylation preferences
75comprise glycopeptide sugar binding to the lectin domain
76which subsequently directs distant acceptor sites (6 to 
7717 residues away) onto the catalytic domain for glycosyla-
78tion as depicted in Figure 1 [1,6]. It has been found that
79both the long-range and short-range glycopeptide prefer-
80ences can operate in an N-terminal or C-terminal direc-
81tion depending on isoenzyme and furthermore some
82isoenzymes possess both the long-range and short-range
83glycopeptide activities (Figure 1). Together, these prop-
84erties explain how a highly coordinated repertoire of
85GalNAc-Ts are capable of readily generating multiple
86closely spaced Tn antigens, as occurs in mucins, as well as
87glycosylating proteins containing only a few acceptor
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Summary of the known peptide and glycopeptide specificities of the GalNAc-T family.
Phylogenetic tree of the GalNAc-Ts showing their 1) random peptide derived peptide substrate motifs as Sequence Logos [7,23,32,46] 2)
neighboring prior glycosylation preferences (1–3 residues) due to catalytic domain interactions [4], and 3) their long-range prior glycosylation
preferences (6 to 17 residues) due to lectin domain binding [23,40]. Note that ‘-ND-’ stands for not determined while ‘- - -’ indicates no or
weak activity. Also note that GalNAc-T8, GalNAc-T9, GalNAc-T18 and GalNAc-T19 exhibit nearly undetectable activities against most substrates
[47] and have not been well characterized. The models at the bottom show the different substrate binding modes that lead to the indicated
specificities. The catalytic and lectin domains are shown as oval-shaped figures in blue and red, respectively. (Glyco)peptides are indicated in
purple while the yellow squares denote the position of prior GalNAc moieties in the glycopeptides. Arrows indicate the position of GalNAc transfer
to the acceptor site.
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88 sites. These combined properties must also be involved
89 in the targeting of specific substrates.
90 The fact that most isoenzymes of this family are capable
91 of glycosylating common acceptor substrates, particularly
92 those containing the (Thr/Ser)ProXPro motif (where ‘X’
93 usually stands for a small hydrophobic residue; see Fig-
94 ure 1), suggests that they may also serve redundant
95 functions [4,7]. Paradoxically, in recent years an incre-
96 mental number of reports have demonstrated that several
97 GalNAc-T isoenzymes are highly specific for certain
98 protein substrates, as identified by the Simple Cell
99 (SC) approach developed by the Clausen group [8,9].
100 Using this strategy, ApoC-III was identified as a specific
101 substrate of GalNAc-T2 [9] and GalNAc-T11 was
102 reported to be specifically involved in glycosylation of
103 the peptide linkers between class A repeats of the LDL
104 receptor family [10,11]. One common theme found for
105 isoenzyme-specific glycosylation is that such a glycosyla-
106 tion can interfere with the proprotein processing of
107 neighboring sites thus controlling such a processing
108 [12]. Two of the most studied examples are GalNAc-
109 T3 and its substrate, the fibroblast growth factor 23
110 (FGF23) [13], as well as GalNAc-T2 and angiopoietin-
111 like Protein 3 (ANGPTL3) [14], where miss-regulation of
O-glycosylation can lead to familial tumoral calcinosis and
112 dyslipidemia, respectively [13,14]. In addition, the aber-
113 rant expression or mutation of several GalNAc-T isoen-
114 zymes and the overexpression of the Tn-antigen is
115 directly associated with many cancers [15,16,17], the
116 mechanisms of which are still not understood, although
117 Tn–Tn self-association may play a role [16]. Finally, the
118 GalNAc-Ts are involved or implicated in many other
119 biological functions including development, receptor traf-
120 ficking and modulation and protein secretion, which are
121 beyond the scope of this review [18].
122 How this family of GTs can glycosylate multiple common
123 sites in some proteins and at the same time be highly
124 isoenzyme-specific for sites in other proteins remains
125 unanswered. Herein, we review the recent advances that
126 have begun to unravel the substrate-recognition mecha-
127 nism of several of the most representative isoenzymes, as
128 well as presenting the structural and kinetic basis for both
129 their overlapping and selective activities.
130 Structural similarities between GalNAc-Ts
131 isoenzymes
132 To obtain a complete understanding of the mechanism
133 underlying the substrate specificity of this family of
134 enzymes, crystal structures of GalNAc-T isoenzymes
135 have been solved, either in the apo form or in complex
136 with (glyco)peptide substrates and products. To date, the
137 following structures have been reported (see Figure 2a
138 and b): a) Mus musculus GalNAc-T1 with Mn2+ (MmGal-
139 NAc-T1) (PDB entry 1XHB) [19]; b) human GalNAc-
140 T2 (HsGalNAc-T2) complexed with UDP-Mn2+ (PDB
141entry 2FFV), a ‘naked’ peptide (PDB entry 2FFU) [20]
142and three glycopeptides (PDB entries 5AJP, 5AJO and
1435AJN) [21]; c) HsGalNAc-T10 complexed with UDP-
144Mn2+ and Ser-GalNAc (PDB entries 2D7I and 2D7R)
145[22]; d) HsGalNAc-T4 complexed with UDP, Mn2+ and
146a glycopeptide (PDB entry 5NQA) [6]; and e) the
147recently reported structures of HsGalNAc-T4 complexed
148with UDP, Mn2+ and a diglycopeptide (PDB entry 6H0B)
149[23] and two splice variants of the fly PGANT9A/B with
150UDP-Mn2+ and a peptide substrate (PDB entries 6E4Q
151and 6E4R; Figure 2b) [24].
152These structures all show an N-terminal catalytic domain
153adopting the typical GT-A fold, characterized by two
154abutting Rossmann-like folds which is linked by a short
155flexible linker to a C-terminal ricin-like lectin domain
156[6,19,20,21,22] (Figure 2a). The lectin domain, a
157unique structural feature only present in this family of
158eukaryotic GTs, has a b-trefoil fold built from three
159repeat units (a, b and g) that are potentially capable to
160bind a GalNAc moiety [25,26]. It should be noted that
161these repeats are not necessarily all active binders based
162on their sequence motif [4] and by experiment [7,27].
163GalNAc-T catalytic domain: UDP-GalNAc
164binding site and flexible loop
165The first crystal structure of a GalNAc-T was for MmGal-
166NAc-T1 [19]. It provided the initial picture of the active
167site for which subsequent GalNAc-T structures highly
168resemble, particularly in the architecture of the critical
169and conserved Mn+2 binding site (formed by Asp209,
170His211 (the DXH motif) and His344). This structure also
171showed that the catalytic and lectin domains were closely
172associated [19] (Figure 2b). Subsequent crystal struc-
173tures of GalNAc-T2 complexed to both UDP-Mn2+ and
174to UDP-Mn2+ and the EA2 peptide (AspSerThrThrProA-
175laProThrThrLys) [20], together with the GalNAc-T10
176crystal structure complexed with hydrolyzed UDP-Gal-
177NAc and Mn2+ [22], further defined the GT-A fold active
178site residues that tethered the uridine diphosphate of the
179UDP-GalNAc donor substrate [20,22]. In addition, the
180structure of GalNAc-T10 catalytic domain revealed the
181GalNAc moiety bound in the UDP-GalNAc-binding
182pocket [22,28]. These structures, as well as the crystal
183structures of the first pre-Michaelis and Michaelis com-
184plexes of HsGalNAc-T2 [29], were of fundamental
185importance for defining models of the dynamics of Gal-
186NAc-T2 during its catalytic cycle, which consists of an
187ordered bi–bi kinetic mechanism [29,30,31]. In addi-
188tion, the Michaelis complex revealed that these GTs
189follow a front-face SNi-type reaction mechanism [29
].
190Structures of GalNAc-Ts, both with and without bound
191peptide substrate, have revealed a dynamic flexible loop
192at the surface of the catalytic domain substrate binding
193site as an important structural feature of the GalNAc-Ts
194[20,21,29]. This flexible loop, formed by residues
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Cartoon and surface representation of GalNAc-Ts structures.
Catalytic and lectin domains are shown in purple and salmon respectively, while flexible loop and linker are displayed in yellow. (a) Extended (left
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195 Arg362 to Ser373 in HsGalNAc-T2, is able to adopt either
196 a closed conformation to form a lid over UPD, rendering
197 the enzyme in an active form, or an open conformation in
198 which the loop folds back to expose UDP to the bulk
199 solvent (inactive form; Figure 2c) [20,29]. This inter-
200 conversion has recently been shown to be dependent of
201 the presence of UDP-GalNAc in HsGalNAc-T2, where
202 this sugar nucleotide stabilizes the closed conformation
203 and consequently allows the binding of the substrate
204 peptide [32]. The importance of this flexible loop in
205 catalysis is exemplified by the molecular basis of the
206 inactivation of the HsGalNAc-T2-Phe104Ser mutant,
207 which is linked to low levels of high density lipoprotein
208 cholesterol [32,33]. It was found that Phe104 controls
209 the inactive-to-active transition of the flexible loop due to
210 its hydrophobic interaction with Ala151/Ile256/Val360, as
211 well as a CH-p interaction with the side-chain of Arg362
212 located in the flexible loop [32]. The hydrophilic
213 Phe104Ser mutation fails to lock the flexible loop in its
214 active form, thus impeding peptide substrate binding and
215 the failure to glycosylate its targeted peptide substrates (i.
216 e. ApoC-III and ANGPTL3). This results in low levels of
217 HDL [32,33,34].
218 GalNAc-T catalytic domain: peptide-binding
219 site
220 It is noteworthy that several GalNAc-T crystals soaked or
221 cocrystallized with (glyco)peptides show indeterminate/
222 disordered structures for the substrate bound to the
223 catalytic domain [6,24]. Nevertheless, structural infor-
224 mation of the GalNAc-T-peptide acceptor recognition
225 could be inferred from the series of structures of (glyco)
226 peptides bound to the HsGalNAc-T2 isoenzyme [21]
227 and very recently the diglycopeptide bound to HsGal-
228 NAc-T4 [23]. In these latter structures the interactions
229 between the transferase and its acceptor substrates are
230 dissimilar, suggesting differences between isoenzymes at
231 the peptide binding groove level. However, this could
232 also be due to the different (glyco)peptides used for both
233 isoenzymes. The HsGalNAc-T2 structures revealed that
234 the EA2 peptide bound in a shallow cleft on the surface of
HsGalNAc-T2, being recognized by hydrophobic inter-
235 actions and to a lesser extent hydrogen bond interactions
236 [20] (see Figure 3a). It was also observed that the methyl
237 group of the acceptor Thr residue was embedded within a
238 hydrophobic pocket, providing a plausible explanation of
239 why most GalNAc-T isoenzymes prefer to glycosylate
240 Thr over Ser acceptor residues [20,21,35] (Figure 3a).
241 Several other crystal structures of HsGalNAc-T2 in com-
242 plex with UDP-Mn2+ and glycopeptides also showed that
243 the glycopeptides acted as bridges between the catalytic
244and lectin domains, where the latter bound the glycopep-
245tide GalNAc [21]. In these structures, UDP and the
246glycopeptides were bound to an adaptable sugar-nucleo-
247tide binding site, with the flexible loop adopting either
248open or closed conformations (Figure 2c). Interestingly,
249the binding of a mono-glycopeptide to GalNAc-T4
250revealed peptide GalNAc binding at the lectin domain
251but no observable peptide electron density in its catalytic
252domain [6] while recently a homologous diglycopeptide
253showed a well-resolved peptide bound to the catalytic
254domain in a closed conformation due to GalNAc-T4’s
255neighboring glycopeptide binding activity (discussed
256below) [23] (Figure 3b). Interestingly, in the Gal-
257NAc-T4 structure, the portion of the peptide spanning
258the catalytic and lectin domains was found disordered
259[21,23].
260At the level of the peptide-binding groove, it was further
261observed that three highly conserved aromatic residues
262(namely Phe361, Phe280 and Trp282 in GalNAc-T2),
263interact with the (Thr/Ser)-Pro-X-Pro substrate sequence
264[20]. Thus far the (Thr/Ser)ProXPro sequence is the only
265substrate consensus motif remotely conserved among
266most GalNAc-Ts (Figures 1, 3a and b) [1,21]. Indeed,
267all isoenzymes that experimentally display this (Thr/Ser)
268ProXPro preference possess the homologus Phe and Trp
269residues [4,7,23] including GalNAc-T4 and Gal-
270NAc-T12. GalNAc-T7 and GalNAc-T10, which lack
271these conserved residues and do not exhibit the (Thr/
272Ser)ProXPro preference, instead display strong neigh-
273bouring glycosylation preferences at the +1 position rela-
274tive to the acceptor (i.e. (Thr/Ser)(Thr*/Ser*), where
275* = -O-GalNAc) [4,28]. These latter two isoenzymes
276are, therefore, expected to contain a GalNAc binding
277site in place of the ProXPro binding site found in the
278other isoenzymes. Presently, the structural and molecular
279bases Q4for the neighboring glycosylation preferences of
280GalNAc-T7 and GalNAc-T10 remain to be determined.
281Thus, the near lack of a conserved substrate consensus
282motif together with their active site flexibility points to
283the versatility of these enzymes, allowing them to sculpt
284their binding sites to accommodate a wide range of
285acceptor substrates.
286GalNAc-T catalytic domain: glycopeptide-
287binding site
288Until very recently there were no structures describing how
289the so-called neighbouring glycosylation activity of the
290GalNAc-Ts could be accommodated. The recent report
291of a diglycopeptide (GlyAlaThr*3GlyAlaGlyAlaGlyAla-
292GlyThr*11Thr12ProGlyProGly, where Thr* = Thr-O-
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(Figure 2 Legend Continued) panel) and compact (right panel) forms of monomeric HsGalNAc-T2. (b) Cartoon and surface representation of
MmGalNAc-T1, HsGalNAc-T4, DmPGANT9A and HsGalNAc-T10. (c) Surface representation of the HsGalNAc-T2-UDP-MUC5AC-13 complex. The
overall structure is shown in salmon, monoglycopeptide MUC5AC-13 and the flexible loop are depicted in cyan and yellow, respectively. The
flexible loop of the enzyme is shown in its closed and open conformations.
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Interactions between GalNAc-Ts and their substrates.
(a) Close-up view of the catalytic domain of HsGalNAc-T2 with two different peptides, EA2 (cyan sticks; left panel) and glycopeptide MUC5AC-13
(GlyThrThrProSerProValProThrThrSerThrThr*SerAlaPro) (yellow sticks; right panel), which are similarly recognized by HsGalNAc-T2 through a
hydrophobic patch. UDP is depicted as sticks with magenta carbon atoms and Mn2+ is shown as a purple sphere. (b) On the left panel, surface
representation of the HsGalNAc-T4-UDP-Diglycopeptide 6 (GlyAlaThr*3GlyAlaGlyAlaGlyAlaGlyThr*11Thr12ProGlyProGly) complex. Peptide
backbone is depicted in cyan with the two GalNAc groups as blue and red sticks; the enzyme flexible loop is shown in its closed conformation in
yellow. On the right panel, close-up view of the main interactions between HsGalNAc-T4 catalytic domain glycopeptide binding-site and the
GalNAc group on T*11 of diglycopeptide 6. The GalNAc-T4 residues forming the peptide-binding site are depicted in salmon and yellow and the
glycopeptide is depicted in cyan, with the GalNAc groups shown as blue and red sticks. Mn2+ and water molecules are depicted as green and red
spheres, respectively, and hydrogen bonds appears as dotted yellow lines. Please note that we only show water-mediated interactions in which
Current Opinion in Structural Biology 2018, 56:1–10 www.sciencedirect.com
293 GalNAc) bound to both the lectin and catalytic domains of
HsGalNAc-T4 now reveals how this occurs at least in one
294 isoenzyme [23] (Figure 3b). In this structure the GalNAc
295 of Thr*11 is shown tethered by hydrogen bond and hydro-
296 phobic interactions to the side chains of Thr283 andGln285
297 and the back bone of Lys366 at the surface of the catalytic
298 domain. Importantly, these residues are not conserved
299 among other GalNAc-T isoenzymes and there is no dis-
300 cernible cleft or pocket for the binding of the GalNAc
301 (Figure 3b). Such GalNAc binding presents the adjacent
302 Thr12 into the correct orientation to accept GalNAc from
303 the UDP-GalNAc donor. Kinetic studies on a series of
304 glycopeptide substrates further confirmed that the neigh-
305 bouring GalNAc binding at the catalytic domain was
306 weaker than the remote GalNAc binding of Thr*3 to the
307 lectin domain and further revealed substrate inhibition
308 kinetics on the diglycopeptide, presumably due to com-
309 petitive binding of the two Thr*’s of the substrate at the
310 lectin domain [23]. This work is of additional significance
311 as the individual GalNAc-T4 remote and neighboring
312 glycopeptide activities, and both together, could be elimi-
313 nated or greatly reduced by selective mutagenesis.
314 GalNAc-Ts lectin domain
315 The GalNAc-T-glycopeptide recognition at the lectin
316 domain is more easily compared among isoenzymes, as
317 there are crystal structures of HsGalNAc-T2, HsGalNAc-
318 T4 and HsGalNAc-T10 complexed with Ser-O-GalNAc
319 as well as longer Thr-O-GalNAc containing glycopeptides
320 [6,21,22,23] (Figure 3c). The GalNAc-T1 lectin
321 domain contains two known functional GalNAc-binding
322 sites out of the possible three (i.e. the a and b subdo-
323 mains) [36], whereas the GalNAc-T2, GalNAc-T4, and
324 GalNAc-T10 lectin domains contain only one known
325 active site (i.e. a-, a- and b-respectively) [4]. The first
326 structure of a glycopeptide bound to the lectin domain,
327 that is, Ser-O-GalNAc bound to HsGalNAc-T10, revealed
328 the sugar moiety bound to the b-site interacting through
329 several hydrogen bonds (including residues Asp525,
330 Asn544, Tyr536) and one CH-p interaction (His539)
331 (Figure 3c). Subsequent structures of GalNAc-T2 com-
332 plexed with longer glycopeptides showed no discernible
333 interactions with the peptide backbone of the lectin
334 domain level, while the GalNAc moiety interacted exclu-
335 sively with residues in the a-subdomain binding site by
336 similar interactions as described for GalNAc-T10 (i.e. via
337 residues Asp458/Asn479/Tyr471 and His474). These resi-
338 dues are conserved in nearly all isoenzymes (Figure 3c)
339 [21,22]. Similarly, binding interactions of the peptide
340 GalNAc residue to the lectin a-domain of GalNAc-T4
341 were recently reported [6,23] (Figure 3c); however, a
342 large difference in the orientation of the lectin domains of
343GalNAc-T4 and GalNAc-T2 relative their catalytic
344domains was observed. As discussed in the sections
345below, these differences readily explain the origins of
346their different long range N-prior or C-prior glycosylation
347preferences (see Figures 1 and 4).
348Earlier work had suggested that the lectin domain of
349GalNAc-Ts could likely influence substrate specificity by
350steric hindrance that would depend on the size of the
351amino acid side chains of the glycopeptide substrate [37],
352while it has also been suggested that the lectin domains of
353some GalNAc-Ts could form hetero-dimers and/or homo-
354dimers that could also alter their specificity [38]. The
355recent crystal structures of the fly PGANT9-A and
356PGANT9-B lectin domain splice variants now offers
357intriguing evidence for something like the former [24
358]. In this case, a loop on the lectin domain that protrudes
359toward the catalytic domain peptide binding site differs in
360charge between the splice variants. These charge
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Superposition of HsGalNAc-T2 and HsGalNAc-T4.
Superimposed cartoon representations of HsGalNAc-T2-UDP-
MUC5AC-13 glycopeptide
(GlyThrThrProSerProValProThrThrSerThrThr*SerAlaPro) complex
depicted in red and HsGalNAc-T4-UDP-diglycopeptide 6 (GlyAlaThr
*3GlyAlaGlyAlaGlyAlaGlyThr*11Thr12ProGlyProGly) complex depicted
in blue. The MUC5AC-13, diglycopeptide 6 and GalNAc moieties are
shown in red, blue, and orange atoms, respectively. The arrows
indicate the direction of the long-range glycosylation preference of
each enzyme, based on the orientation of their respective lectin
domains with respect their catalytic domains. Note that the critical Asp
residues of the lectin domain GalNAc-binding sites are indicated for
clarification purposes.
(Figure 3 Legend Continued) only the water molecule act as a bridge between the residues. (c) Main interactions between GalNAc-T2, GalNAc-
T4 and GalNAc-T10 isoenzymes lectin domain (shown as salmon, purple and slate, respectively) and the GalNAc moiety (shown as sticks with
orange carbon atoms).
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361 differences correlate with their activities toward highly
362 charged substrates, thus suggesting that at least electro-
363 static interactions, if not direct peptide substrate binding,
364 of the lectin domain can significantly influence transfer-
365 ase activity [24]. Biologically, these splice variances are
366 used to properly glycosylate different secretory mucins,
367 whose incomplete glycosylation is shown to alter secre-
368 tory granule morphology [24]. Concurrently, structural
369 and molecular dynamics studies on GalNAc-T4 bound to
370 a diglycopeptide have revealed a flexible loop on its lectin
371 domain that can approach the GalNAc residue of catalytic
372 domain bound glycopeptide [23]. Mutagenesis of this
373 loop was shown to alter the kinetic properties of GalNAc-
374 T4 against both peptide and glycopeptide substrates thus
375 again confirming that additional features of the lectin
376 domain beyond glycan binding will likely play roles in
377 substrate selection of these transferases.
378 The flexible linker and its role in the remote
379 glycosylation preferences of the GalNAc-Ts
380 The catalytic and lectin domains of all of the GalNAc-Ts
381 (except for T20 that lacks the lectin domain) are connected
382 by a linker sequence whose length and sequence varies
383 among isoenzymes [6,19,20,21,22]. Comparing lin-
384 kers, the N-terminal regions are more conserved while the
385 C-terminal regions are less conserved [6]. Previous stud-
386 ies have attributed the relative positioning of the catalytic
387 and lectin domains to the nature of the linker sequence
388 [21,39], thus the more stretched-out linker of GalNAc-
389 T10 [22] results in fewer interactions between both
390 domains compared to the more closely spaced domains
391 in GalNAc-T1 [19] (Figure 2b). This suggested that linker
392 flexibility could function to control the relative orientation
393 of lectin and catalytic domains, therefore, modulating the
394 selection of new GalNAc-modification sites in previously
395 glycosylated substrates [4,39,40].
396 One of the largest questions in the field has been how
397 these enzymes differentially recognize remote prior gly-
398 cosylation sites in an N-terminal or C-terminal direction.
399 A recent work on HsGalNAc-T2 and HsGalNAc-T4
400 shows that their flexible linkers display both interdomain
401 rotation and interdomain translational-like motion which
402 could be responsible of their different long range glyco-
403 peptide preferences [6]. The crystal structure of HsGAl-
404 NAc-T4 with glycopeptide bound to the lectin domain
405 [6] revealed that its GalNAc-binding site was located on
406 the opposite side of the lectin domain when compared to
407 the homologous site in HsGalNAc-T2 (Figure 4). These
408 different positions of the lectin domain (Figure 4), readily
409 account how GalNAc-T4 promotes the opposite long-
410 range glycosylation preference compared to GalNAc-T2
411 and other isoenzymes [1,4] (see Figure 1). That this
412 rotation is caused by the nature of the flexible linker was
413 supported by molecular dynamics simulations, site-
414 directed mutagenesis, and kinetics experiments [6].
415 Indeed, the glycopeptide kinetics of GalNAc-T2
416chimeras containing a GalNAc-T3 or GalNAc-T4 flexible
417linker and a series of flexible linker mutants, demon-
418strated that its long-range glycosylation preference could
419be modulated and even reversed simply by modifying its
420linker [6]. This suggests that the flexible linker plays a
421major role in dictating each isoenzyme’s long-range gly-
422cosylation preference by altering the lectin domain’s
423orientation relative to its catalytic domain [6]. All
424together, these findings showed for the first time how a
425structural feature that is neither in the active site nor in
426the lectin domain GalNAc-binding site is capable of
427modifying the activity and the glycosylation preferences
428of these isoenzymes.
429Final remarks
430That the GalNAc-Ts are associated with numerous human
431diseases including cancer [14,15,16,41] clearly justifies the
432importance of unravelling the molecular basis that lie
433beneath their substrate recognition, ranging from redun-
434dant overlapping sites [42] to highly specific targets. Here,
435we have briefly summarized the most important advances
436at structural level of this family of enzymes that begin to
437reveal the molecular origins of their unique peptide and
438glycopeptide specificities. However, additional structures
439of these isoenzymes in complex with both their redundant
440and specific (glyco)peptide substrates will be necessary for
441a thorough mechanistic understanding of their promiscuity,
442specificity, and distinct glycosylation preferences. In par-
443ticular, much more needs to be understood regarding their
444short-range glycosylation preferences as we currently have
445only one example describing such GalNAc-T-(glyco)pep-
446tide recognition. Hence, it is of utmost importance to
447continue studying this complex family of enzymes to fully
448understand how they selectively recognize their targets in
449multiple signaling pathways. Such studies will in turn
450facilitate the development of GalNAc-T modulators and
451inhibitors thatwouldcertainlybeuseful for the treatmentof
452many diseases [11,13,16,43,44]. Finally, one cannot dis-
453card the potential for Nature organizing the GalNAc-T’s in
454a cell according to their isoenzyme class (e.g. early, inter-
455mediate and late GTs) utilizing their different glycosyla-
456tion preferences to produce the vast repertoire of glycosyl-
457ation sites observed in vitro. Such organization is clearly
458present as the retrograde introduction of GalNAc-Ts into
459the ER (the so called GALA pathway) has been shown to
460manifestly alter the patterns of O-glycosylation and may
461play a role in cancer [26,41]. However, this pathway is
462currently under an intense debate in the Glycobiology
463community hence its importance has yet to be fully under-
464stood [45].
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